OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
OKYO Pharma Limited (OKYO.L) Appointment of Chief Scientific Officer
OKYO announces the appointment of Dr Rajkumar Patil as Chief Scientific Officer
OKYO Pharma Limited (OKYO.L) Patent for treating Ocular Pain and Inflammation
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
OKYO PHARMA LIMITED (OKYO.L) Filing patent application for the use of Chemerin
OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
OKYO PHARMA LIMITED (OKYO.L) Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board
OKYO , the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce
OKYO PHARMA LIMITED (OKYO.L) Dr James Khodabakhsh MD named Chairman of the SAB
Dr James Khodabakhsh MD named Chairman of the Scientific Advisory Board at OKYO Pharma Ltd